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CD8+ T-cell-mediated suppression of feline immunodeficiency virus (FIV) replication has been described by several groups, although the
mechanisms of activation and conditions for viral suppression vary with the methodologies. We have previously reported that CD8+ T-cell-
mediated suppression of FIV replication required inducer cell stimulation of the effector cells. The focus of the present study was to examine
the essential role of inducer cells required for the induction of this soluble anti-FIV activity. Both FIV-PPR-infected T cells and feline skin
fibroblasts (FSF) infected with an alphavirus vector expressing FIV capsid or the irrelevant antigen lacZ, stimulated autologous or
heterologous effector cells to produce supernatants that suppressed FIV replication. Thus, induction of this suppression of FIV replication did
not strictly require autologous inducer cells and did not require the presence of FIVantigen. Anti-viral activity correlated with the presence of
CD8+ T cells. Suppression was maximal when the inducer cells and the effector cells were in contact with each other, because separation of
the inducer and effector cells by a 0.45-Am membrane reduced FIV suppression by approximately 50%. These findings emphasize the
importance for membrane antigen interactions and cytokines in the optimal induction of effector cell synthesis of the soluble anti-FIVactivity.
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Feline immunodeficiency virus (FIV) is a T-lympho-
tropic lentivirus in the family Retroviridae (Pedersen et
al., 1987). Natural or experimental FIV infection of cats
results in a transmissible AIDS-like disease, similar to that
observed with human immunodeficiency virus (HIV) infec-
tion in humans (Pedersen et al., 1989; Yamamoto et al.,
1988).
CD8+ T cells are a critical component of cellular
immune protection against HIV infection. CD8+ T lym-
phocytes control HIV, SIV and FIV infection through
both cytotoxic (CTL) and non-cytotoxic mechanisms
(Appay et al., 2000; Barker, 1999; Barouch and Letvin,
2001; Blackbourn et al., 1994; Brinchmann et al., 1990;0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.11.016
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E-mail address: ecollisson@cvm.tamu.edu (E.W. Collisson).Charaf et al., 1993; Choi et al., 2000; Flynn et al.,
2002; Furci et al., 2002; Geiben-Lynn et al., 2001;
Hohdatsu et al., 2000; Jeng et al., 1996; Kannagi et
al., 1988; Le Borgne et al., 2000; Mackewicz et al.,
1994; Pollack et al., 1997; Powell et al., 1990; Song et
al., 1992; Walker, 1993; Walker et al., 1986; Yang et al.,
1997). Non-cytotoxic responses of CD8+ T lymphocytes,
a type of innate immunity, may be more important than
the cytotoxic responses in controlling certain viral infec-
tions (Levy, 2001). This CD8+ non-cytotoxic antiviral
response is thought to be mediated, at least in part, by
an undefined secreted CD8+ antiviral factor (CAF)
(Clerici et al., 1996; Levy, 2001; Levy et al., 1996).
Such non-cytotoxic activity is not HIV-specific nor
species-specific, is not restricted by HLA class I or
class II molecules and is identified immediately after
acute HIV infection (Levy, 2001; Mackewicz et al.,
1998; Walker et al., 1991a). The levels of CD8+ anti-
HIV responses have been correlated with CD4 counts
and the absence of infection in individuals repeatedly
exposed to HIV and in HIV-infected, long-term survivors
Table 1
Requirement of FIV-infected inducer T cells for stimulation of the effector
cells for the production of the soluble anti-FIV activity
Cats Viral antigen expression in supernatants from
target cells that received supernatants from
effector cells which were not stimulated by
inducer T cellsa
Capsid optical
density (OD)b
% Virus
expressionc
FIV ()
OAE5 2.18 116.6
OLQ4 2.41 128.9
FIV (+)
AUO2 2.77 148.1
AUO3 1.74 93.0
AZV2 2.32 124.1
OLQ5 1.8 96.3
OLM6 2.57 137.4
AWF1 2.35 125.7
Controld 1.87 100.0
a Cell culture supernatants were collected from effector cells (not stimulated
by the FIV-infected inducer T cells) after 7 days, ultracentrifuged and added
at a medium to supernatant ratio of 1:1 to FIV-PPR-infected target cells
every 3 days.
b FIV capsid antigen was measured by an FIV capsid antigen detection
enzyme-linked immunosorbent assay (ELISA) as mentioned in the
Materials and methods. The standard deviations ranged from 0.1 to 0.23
for these values.
c Relative to virus expression of control cells.
d These control cells were infected with FIV-PPR and cultured in complete
medium without effector cell supernatant.
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al., 1994; Landay et al., 1993; Levy, 2001; Mackewicz
et al., 1991; Stranford et al., 1999). In contrast, Cope-
land et al. (1997) did not find any correlation between
the extent of CD8+ T-cell-mediated suppression and
clinical stage of infection or CD4+ T-cell counts in
HIV-1-infected individuals.
CD8+ T-cell-mediated suppression of FIV replication
has been described by several groups, although the mech-
anisms of activation and conditions for viral suppression
vary with the methodologies (Bucci et al., 1998a; Choi et
al., 2000; Crawford et al., 2001; Flynn et al., 1999, 2002;
Hohdatsu et al., 1998, 2000, 2002; Jeng et al., 1996). In
our studies, reproducible production of non-cytotoxic anti-
FIV activity from CD8+ T lymphocytes, from cats in the
asymptomatic stage of FIV infection, has been maximally
achieved in vitro with effector cells stimulated by FIV-PPR
strain-infected inducer T cells rather than mitogen (Choi et
al., 2000).
Whereas a number of studies have attempted to
characterize the CD8+ T cells responsible for generating
lentivirus suppression (Bucci et al., 1998b; Flynn et al.,
2002; Gebhard et al., 1999; Landay et al., 1993; Toso et
al., 1995; Zanussi et al., 1996) or have focused on
characterizing the CD8+ antiviral activity (Geiben-Lynn
et al., 2001; Mosoian et al., 2000), there is little known
about the physiologic stimulus that activates the effector
CD8+ T cells to generate suppressing activity. Previous
reports suggested that HIV infection or a potential
exposure to the virus was needed for the CAF activity
(Levy et al., 1998; Walker et al., 1991b). However, the
fact that the CD8+ T-cell antiviral response has been
observed in asymptomatic HIV-infected individuals
(Blackbourn et al., 1996; Brinchmann et al., 1990; Hsueh
et al., 1994; Mackewicz et al., 1991; Toso et al., 1995),
HIV exposed but uninfected individuals (Furci et al.,
2002; Levy et al., 1998; Stranford et al., 1999) and
healthy HIV-naı¨ve individuals (Kootstra et al., 1997;
Rosok et al., 1997), as well as in FIV-infected and -un-
infected cats (Choi et al., 2000), suggests that mecha-
nisms involved for the induction of this antiviral response
are not virus-specific.
Because the CD8+ antiviral activity seems to be non-
specific with respect to HIV or FIV, the elicited immune
response would seem to be of an innate nature. Both
soluble and cellular components contribute to innate im-
munity (Levy, 2001), resulting in a general response of the
immune system to an infection without specificity for a
target antigen. Identifying the conditions leading to the
induction of this antiviral activity is essential in exploiting
this innate control of lentiviral infection. Here we report
for the first time, that feline skin fibroblasts (FSF) could be
used as inducer cells to mediate the soluble anti-FIV
activity and the importance of inducer cell–effector cell
contact in the generation of optimal suppression of FIV
replication in vitro.Results
Production of the soluble anti-FIV activity requires
stimulation by inducer cells which do not have to be
MHC-restricted
We have previously reported that the soluble anti-FIV
activity was secreted from PBMC of both FIV-infected and
-uninfected cats after stimulation with autologous FIV-
infected inducer T cells, in contrast to stimulation with
concanavalin A (Con A) (Choi et al., 2000). Supernatants
from the PBMC of two uninfected cats OAE5 and OLQ4
and six FIV-infected cats AUO2, AZV2, OLM6, AUO3,
OLQ5 and AWF1 induced virus expression rather than
suppressing virus replication, when FIV-infected target
cells were treated with cell culture supernatants of effector
cells not stimulated with infected inducer T cells (Table 1).
This confirmed that production of the soluble anti-FIV
activity from the effector cells of these animals requires
stimulation by exogenously added inducer cells.
It was further determined as to whether inducer and
effector cells required MHC compatibility to stimulate the
anti-FIV activity. Therefore, inducer T cells were obtained
from autologous or heterologous donors as compared to the
source of effector cells. Cell culture supernatants collected
on day 7, from PBMC stimulated by irradiated MHC-
matched autologous or irradiated MHC-mismatched heter-
Table 3
Induction of the soluble anti-FIV activity by effector cells stimulated by
FSF expressing FIV capsid
Cats Viral antigen expression in supernatants from target cells that
received supernatants from effector cells which were stimulated
by autologous
FSF cells expressing FIV
capsida
FSF cells not expressing FIV
capsidb
Capsid ODc % Virus
expressiond
Capsid OD % Virus
expression
FIV (+)
AUO2 0.08 F 0.03* 4.1 2.88 F 0.49 148.5
AUO3 0.05 F 0.00* 2.6 1.16 F 0.23* 59.8
AWF1 0.13 F 0.02* 6.7 2.75 F 0.70 141.8
AZV2 0.24 F 0.06* 12.4 1.19 F 0.56* 61.3
OLQ5 0.40 F 0.13* 20.6 2.68 F 0.98 138.1
FIV ()
OAE5 0.34 F 0.07* 17.5 1.45 F 0.26 74.7
Controle 1.94 F 0.41 100.0 1.94 F 0.41 100.0
a Effector cells were stimulated with autologous, irradiated FSF expressing
FIV capsid for 7 days. The supernatants collected from the stimulated cells
on the seventh day were ultracentrifuged and added at a medium to
supernatant ratio of 1:1 to FIV-PPR-infected target cells every 3 days.
b
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suppressive activities in all cats examined, four FIV-infected
(AUO2, AUO3, AZV2 and OLQ5) and two FIV-uninfected
cats (AUS3 and OAE5) (Table 2). Supernatants collected on
day 7, from PBMC of cats OAE5, AUO2, AZV2 and OLQ5
obtained following stimulation by MHC-matched inducer T
cells demonstrated somewhat stronger FIV suppression than
supernatants obtained after stimulation by MHC-mis-
matched inducer T cells (Table 2). In contrast, supernatants
collected on day 7, from PBMC of cats AUS3 (FIV-
uninfected) and AUO3 (FIV-infected) stimulated by
MHC-mismatched inducer T cells demonstrated even more
potent suppression of FIV replication, than supernatants
from PBMC stimulated by MHC-matched inducer T cells
(Table 2). Therefore, the induction of the anti-FIV activity
from feline PBMC was not MHC-restricted.
Use of FSF as inducer cells
The studies, thus far, have depended on FIV-infected T
cells for efficient induction of the anti-FIV activity. To
determine if other types of cells could also be used asTable 2
Effect of MHC-matched and MHC-mismatched inducer T cell stimulation
on the production of the soluble anti-FIV activity
Cats Viral antigen expression in supernatants from target cells that
received supernatants from effector cells which were stimulated
by
Irradiated MHC-matched Irradiated MHC-mismatched
Inducer T cellsa Inducer T cellsb
Capsid ODc % Virus
expressiond
Capsid OD % Virus
expression
FIV ()
AUS3 1.22 F 0.31* 34.1 0.73 F 0.06* 20.4
OAE5 0.77 F 0.04* 21.5 1.46 F 0.04* 40.8
FIV (+)
AUO2 0.47 F 0.04* 13.1 0.85 F 0.06* 23.7
AUO3 0.42 F 0.05* 11.7 0.35 F 0.01* 9.8
AZV2 1.70 F 0.26* 47.5 1.77 F 0.08* 49.4
OLQ5 1.06 F 0.07* 29.6 1.27 F 0.05* 35.5
Controle 3.58 F 0.09 100.0 3.58 F 0.09 100.0
a Effector cells were stimulated with irradiated MHC-matched FIV-infected
inducer T cells for 7 days. The supernatants collected from the stimulated
cells on the seventh day were ultracentrifuged and added at a medium to
supernatant ratio of 1:1 to FIV-PPR-infected target cells every 3 days.
b Effector cells were stimulated with irradiated MHC-mismatched FIV-
infected inducer T cells for 7 days. The supernatants collected from the
stimulated cells on the seventh day were ultracentrifuged and added at a
medium to supernatant ratio of 1:1 to FIV-PPR-infected target cells every 3
days.
c FIV capsid antigen was measured by an FIV capsid antigen detection
ELISA as mentioned in the Materials and methods. Data represent the mean
F SE for the experiments.
d Relative to virus expression of control cells.
e These control cells were infected with FIV-PPR and cultured in complete
medium without effector cell supernatant.
*Statistically significant at a P value of <0.05.
Effector cells were stimulated with autologous, irradiated FSF not
expressing the FIV capsid for 7 days. The supernatants collected from the
stimulated cells on the seventh day were ultracentrifuged and added at a
medium to supernatant ratio of 1:1 to FIV-PPR-infected target cells every 3
days.
c FIV expression was determined by use of an FIV capsid antigen detection
ELISA as mentioned in the Materials and methods.
d Relative to virus expression of untreated control cells.
e These control cells were infected with FIV-PPR and cultured in complete
medium without effector cell supernatant.
*Statistically significant at a P value of <0.05.inducer cells, SV40-transformed FSF were infected with
Semliki Forest virus (SFV) vector recombinant particles
expressing FIV capsid. These cells replaced T cells as
inducer cells. Supernatants collected on day 7, from cells
of the cats whose PBMC were stimulated by autologous
irradiated FSF cells expressing FIV capsid, strongly sup-
pressed FIV replication (Table 3). Suppression observed
using FSF as inducer cells was quantitatively equivalent to
that observed using inducer T cells. Supernatants collected
on day 7 from PBMC cultured with autologous irradiated
FSF not expressing FIV capsid did not demonstrate detect-
able FIV-suppressive activity, with the exception of super-
natants from PBMC of the two FIV-infected cats AUO3 and
AZV2, which suppressed virus replication very weakly (as
determined by the 65% viral expression limit). These results
indicated that FSF expressing a virus antigen could be used
as inducer cells.
CD8+ T lymphocytes are responsible for the suppression of
FIV replication when FSF are used as inducer cells
CD8+ T lymphocytes were enriched by negative selec-
tion to ensure that the CD8+ T-lymphocyte population
Fig. 1. Kinetics of the induction process using CD8+ T lymphocytes as effector cells when FSF were used as inducer cells. FSF prepared from cat AZV2 were
transfected with SFV vector expressing FIV capsid, an irrelevant antigen such as lacZ or SFV vector expressing only its polymerase, or left untransfected.
CD8+ T lymphocytes enriched from fresh PBMC from FIV-infected cats AZV2 (a), AUO2 (b) and FIV-uninfected cat AUS3 (c) were overlaid on FSF. Every 2
days, the supernatants were collected and stored at 4jC and the non-adherent cells were overlaid on newly transfected FSF. As controls, supernatants were
collected from untransfected FSF cultured without CD8+ T lymphocytes, CD8+ T lymphocytes cultured in the absence of FSF and CD8+ T lymphocytes co-
cultured with untransfected FSF. The supernatants were ultracentrifuged and added to FIV-PPR-infected target cells (cat OAE5 PBMC) every 3 days at a
medium to supernatant ratio of 1:1. FIV production was determined by use of an FIV-capsid antigen detection ELISA. All the values have been normalized
with respect to values obtained for untransfected FSF cultured without CD8+ T lymphocytes.
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Table 4
Effect of cell contact between effector cells and inducer cells on induction
of the soluble anti-FIV activity
Cats Viral antigen expression in supernatants from target cells that
received supernatants from effector cells which were
In contact with inducer
T cellsa
Not in contact with
inducer T cellsb
Capsid ODc % Virus
expressiond
Capsid OD % Virus
expression
FIV (+)
AUO3 0.13 F 0.01* 4.3 0.28 F 0.02* 9.2
AWF1 0.51 F 0.03* 16.8 0.98 F 0.14* 32.2
AZV2 0.77 F 0.02* 25.3 1.61 F 0.31* 53.0
E238 3.90 F 0.07 101.6 3.78 F 0.21 124.3
E284 1.91 F 0.55* 62.8 3.88 F 0.13 127.6
OLQ5 0.41 F 0.13* 13.5 3.75 F 0.12 123.4
Controle 3.04 F 0.61 100.0 3.04 F 0.61 100.0
a Effector cells were co-cultured with FIV-infected irradiated autologous
inducer T cells such that they were in contact with each other. Cell culture
supernatants collected after 7 days were ultracentrifuged and added at a
medium to supernatant ratio of 1:1 to FIV-PPR-infected target cells every 3
days.
b Effector cells were co cultured with FIV-infected irradiated autologous
inducer T cells such that they were separated by a 0.45-Am membrane in a
transwell plate. Cell culture supernatants collected after 7 days were
ultracentrifuged and added at a medium to supernatant ratio of 1:1 to FIV-
PPR-infected target cells every 3 days.
c FIVexpression was determined by an FIV capsid antigen detection ELISA
as mentioned in the Materials and methods.
d Relative to virus expression of untreated control cells.
e These control cells were infected with FIV-PPR and cultured without
effector cell supernatant.
*Statistically significant at a P value of <0.05.
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replication in vitro. This population of CD8+ T lymphocytes
contained not more than 5% macrophages and not more
than 10% CD4+ T lymphocytes as determined by flow
cytometry (data not shown). The kinetics of the soluble
anti-FIV activity was determined using cat AZV2 FSF as
inducer cells and enriched CD8+ T lymphocytes from FIV-
infected cats (AZV2 and AUO2) and an FIV-uninfected cat
(AUS3) as effector cells. Supernatants were collected every
2 days from the co-culture of FSF transfected with SFV
vector expressing FIV capsid, and autologous or heterolo-
gous CD8+ T lymphocytes. In the presence of these FSF,
supernatants collected on days 2 and 4 demonstrated the
greatest suppression for the three cats examined. Similar
results were obtained when fresh PBMC were used as
effector cells (data not shown). However, in contrast to
studies using PBMC as a source of effector cells, when
CD8+ T cells were used as effector cells, suppression of FIV
replication was not only observed on day 6, but greater
suppression was observed using supernatants collected on
days 2 and 4 of induction (Figs. 1a–c). The presence of
macrophages and/or CD4+ T cells may either dilute the
suppression or actively inhibit the suppressive activity of
CD8+ T effector cells.
Interestingly, following induction with FSF transfected
with SFV vector expressing an irrelevant antigen such as
lacZ or SFV vector by itself, supernatants from effector
CD8+ T cells of infected cats (AZV2 and AUO2) and an
uninfected cat (AUS3) were also able to suppress FIV
replication in vitro (Figs. 1a–c). This was also observed
when PBMC were used as effector cells (data not shown).
SFV vector without an insert expresses only the polymer-
ase gene of the SFV during the course of transcription. It
is possible that the polymerase or the viral RNA stimulates
the effector cells, demonstrating that this kind of induction
is not specific for FIV. Supernatants obtained from non-
transfected FSF were not able to suppress FIV replication
on any of the days examined. Supernatants from effector
CD8+ T cells cultured without FSF did not demonstrate
any suppressing activity on any of the days examined
(Figs. 1a–c). In addition, supernatants obtained from CD8+
T cells co-cultured with non-transfected FSF did not show
any suppressing activity (Figs. 1a–c). Thus, again non-
transfected FSF cells could not induce CD8+ T cells to
produce anti-FIV activity.
Maximum suppression of FIV replication is dependent on
inducer cell–effector cell contact
Transwell cell culture plates were used to examine
whether cell contact-mediated stimulation was necessary
for the production of the soluble anti-FIV activity. Sup-
pression was consistently lower, although never eliminat-
ed, when a 0.45-Am membrane in transwell dishes
separated the autologous irradiated inducer T cells and
the effector cells. When supernatants collected on day 7from effector cells in contact with the inducer cells were
added to FIV-PPR-infected target cells, all supernatants
with the exception of supernatant from cat E238 (at 2
years post-infection), demonstrated strong suppression of
virus replication (Table 4). Presently, at 4 years post-
infection, effector cells from cat E238 are able to suppress
replication of FIV in vitro (unpublished data). When
supernatants collected on day 7 from effector cells with-
out direct contact with inducer cells were added to target
cells, half suppressed virus replication (FIV-infected cats
AUO3, AWF1 and AZV2); however, supernatants from
the remaining FIV-infected cats E238, E284 and OLQ5
did not (Table 4). Overall, the amount of suppression of
FIV replication observed with the supernatants collected
when the inducer and effector cells were in contact with
each other was reduced by approximately 50% when the
inducer and effector cells were separated in a transwell
plate. Therefore, inducer cell contact was required for
optimal stimulation of effector cells for production of the
soluble anti-FIV activity.
The kinetics of the induction process using transwell
culture plates indicated that the supernatants obtained from
the co-culture of the autologous irradiated inducer T cells
and the effector cells in contact with each other were able
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this suppression was lost by the sixth day (Fig. 2b) for
FIV-infected cats AZV2, AUO2 and FIV-uninfected cat
AUS3. However, when the inducer cells and the effector
cells from FIV-infected cats AZV2 and AUO2 were
separated by a 0.45-Am membrane, the amount of sup-
pression of virus replication seen on the third day was
again reduced by nearly half of that seen when the
inducer and the effector cells were in contact with each
other. Effector cell supernatant from FIV-uninfected cat
AUS3 was able to suppress FIV replication on either day
3 or day 6, but only marginally as compared with the
infected cats. The supernatants from the PBMC cultured
in the absence of inducer cells did not suppress FIV
replication either on day 3 or day 6 for any of the cats
examined (Figs. 2a and 2b). Thus, under the conditions
where FSF were used as inducer cells or when FIV-
infected inducer T cells were separated from the effector
cells, the optimal days for the induction of the soluble
anti-FIV activity continued until the fourth day of induc-
tion, after which a decrease in the anti-FIV activity was
consistently seen.Fig. 2. Kinetics of inducer cell –effector cell contact for the induction process
uninfected cat AUS3 were co-cultured in contact with autologous irradiated FIV-i
membrane. Cell culture supernatants collected on days 3 (a) and 6 (b) were ultra
every 3 days at a medium to supernatant ratio of 1:1. FIV production was determ
asterisks are significant (as calculated by the t test) among the three parameters eDiscussion
These studies suggest that more than one pattern of
induction stimulates antiviral activity in our chronically
FIV-infected and -uninfected control cats. Studies per-
formed in our laboratory consistently indicate that it is
the CD8+ T cells within the population of PBMC that are
responsible for the soluble anti-FIV activity (Choi et al.,
2000; Figs. 1a–1c). The various patterns of induction may
stimulate several molecules that mediate CD8+ T-cell
suppressive activity against FIV. It is likely that the
mechanism of induction differs quantitatively and maybe
even to a greater extent, qualitatively, leading to the
induction of distinct antiviral factors. Moriuchi et al.
(1996) have demonstrated that the HIV suppressor activity
of CD8+ T-cell supernatants is multifactorial and that
various factors within these supernatants including, but
not limited to, the h-chemokines, may affect HIV repli-
cation at various stages of the life cycle of the virus. Due
to the distinct CD8+ T-cell suppressor activities that have
been reported from various laboratories, Copeland (2002)
has also suggested that the CAF activity in humans could. Fresh PBMC (effector cells) from FIV-infected cats AZV2, AUO2 and
nfected inducer T cells or separated from the inducer T cells by a 0.45-Am
centrifuged and added to FIV-PPR-infected target cells (cat OAE5 PBMC)
ined by use of an FIV capsid antigen detection ELISA. Values indicated by
xamined, at 3 days for FIV-infected cats AZV2 and AUO2.
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various modes of induction lead to the secretion of several
molecules mediating the CD8+ T-cell suppressive activity
against FIV, and by inference, HIV. Suppression of FIV
replication in our cats likely depends on the distinct
patterns of induction resulting from the differences in
the innate immune system of the cats, the course of
infection and illness, and the differences in the genetics
of the cats. The levels of suppressing activity generated
have remained highly reproducible for each animal over
several years, although variable from cat to cat. Interest-
ingly, at 2 years post-infection, lymphocytes from cat
E238, infected with the highest dose of FIV-PPR (1250
TCID50), did not produce detectable soluble anti-FIV
activity (Table 3), but had the highest levels of CTL
activity (Choi et al., 2000). Presently, E238, after more
than 4 years of infection, is able to suppress replication of
FIV (unpublished data). All the FIV-infected cats in our
colony have been infected between 3 and 5 years and are
in the chronic asymptomatic stage of infection. The
proviral load of these cats has been found to inversely
correlate with their ability to suppress FIV replication in
vitro (manuscript under preparation). It is possible that the
suppressing activity of the CD8+ T cells actually helps to
maintain the asymptomatic nature of the cats, because as
yet, we have been unable to demonstrate anti-FIV CD8+
T-cell-suppressing activity in acutely infected cats. The
various types of cells that function in the induction of the
effector cells and the communication required for the
induction of the antiviral activity against FIV or HIV have
not yet been defined. The focus of this study was to
determine the requirements for induction of suppression of
FIV replication, specifically whether T cells were neces-
sary for induction of the feline CD8+ T-cell-suppressing
activity and whether FIV infection was a criterion for cells
to function as inducer cells. Inducer cells used in our
initial studies were irradiated FIV-infected T lymphocytes
(Choi et al., 2000). But immortalized FSF, transfected with
SFV vector expressing either the FIV capsid or an
irrelevant antigen, such as lacZ or FSF transfected with
SFV vector expressing only its polymerase, could also
mediate the induction. Either irradiated or non-irradiated
FSF could serve as inducer cells. The use of FSF trans-
fected with SFV vector expressing the capsid protein of
the FIV-PPR strain might serve as a convenient alternative
to the use of infected T cells as inducer cells in our
system. This is the first published report of FSF, trans-
fected with SFV-capsid, SFV-lacZ or SFV only, serving as
inducer cells to stimulate the soluble anti-FIV activity.
Thus, it appears that functional inducer cells do not need
to be professional antigen presenting cells (APC) and
these cells do not have to express the viable and complete
virus.
The effector cells produced the soluble anti-FIV activity
in the absence of MHC-matched inducer cells when either
FIV-infected T cells or transfected FSF were used. This hasbeen shown in our studies using autologous or heterolo-
gous inducer cells to stimulate the effector cells. This is in
contrast to the MHC class I-restricted, FIV-specific cyto-
toxic responses described for CD8+ T cells from our FIV-
infected cats, where autologous FIV-infected T cells were
used as APC (Song et al., 1992). The fact that supernatants
from the co-culture of effector cells (from FIV-uninfected
cat AUS3 and FIV-infected cat AUO3) and mismatched
inducer T cells were able to suppress FIV to a greater
extent is in accordance with our studies using FSF as
inducer cells. In the studies with FSF, we have consistently
shown that supernatants from effector cells (either
PBMC—data not shown or CD8+ T cells—Figs. 1a–1c)
when co-cultured with mismatched FSF transfected with
SFV vector expressing either the FIV capsid or an irrele-
vant antigen, such as lacZ or FSF transfected with SFV
vector expressing only its polymerase, suppress FIV rep-
lication. In our studies, non-transfected FSF alone do not
induce effector cells and although MHC restriction is not
required for the soluble anti-FIV response, it is not yet
clear as to whether it might improve or otherwise contrib-
ute to the activation of the effector cells.
Optimal induction of the suppressing activity from the
effector cells depended on cell–cell contact between in-
ducer and effector cells, although approximately 50% of
the suppressing activity could be demonstrated when the
inducer and the effector cells were not in contact with each
other. Therefore, membrane antigen interactions may be
critical in the communication, while cytokines may play an
accessory role in the induction process.
The kinetics of the induction process demonstrated that
antiviral activity against FIV was maximally expressed until
day 4 after induction, but it was reduced appreciably or was
absent by the sixth day. However, suppression by cell culture
supernatants collected on the seventh day indicates that
accumulation of antiviral factors from day 1 to day 7
contributed to suppression of FIV replication when accumu-
lative supernatants were collected on day 7. This demon-
strates that the antiviral activity is stable over the 7-day
period. Thus, understanding the mechanisms that activate
and control suppression of FIVmay lead to our understanding
of the natural process for controlling chronic lentiviral
infection.
FIV-infected T cells and FSF transfected with SFV
vector expressing the FIV capsid, an irrelevant antigen such
as lacZ or FSF transfected with SFV vector only, could be
used to induce the effector cells to suppress FIV replication
in vitro. Both FSF and FIV-infected T cells would seem to
require communication of some kind of crisis to induce the
effector cells. Identifying alterations occurring with respect
to membrane antigen expression within these two types of
inducer cells will be valuable in understanding conditions
needed for induction of effector cell synthesis of antiviral
activity. Characterization and identification of the stimuli
and mechanisms involved in the induction of the antiviral
activity against FIV, not addressed in other studies, will
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of this innate T-cell immunity and may contribute to the
design of novel, safe and complementary anti-FIV thera-
peutic strategies.Materials and methods
Experimental animals
Specific, pathogen-free cats purchased from Harlan
Sprague–Dawley, Madison, WI, or Liberty Laboratories,
Liberty Corner, NJ, were serologically negative for feline
leukemia virus. Cats were housed in a specific, pathogen-
free environment at the Laboratory Animal Research and
Resources Facility, Texas A&M University, College Station,
TX. Cats AUO2, AUO3, AWF1, AZV2, OLQ5, OLM6,
E238 and E284 were chronically infected with FIV-PPR
strain. From 3 to 5 years previously, 50–1250 TCID50 of
virus had been administered i.v. Cats AUS3, OAE5 and
OLQ4, sham inoculated with saline solution, were used as
negative control cats.
Virus
FIV-PPR was propagated in feline PBMC. After 7–10
days of infection, virus replication was evaluated with an
FIV capsid antigen detection ELISA (Choi et al., 2000).
Supernatants with an OD of more than 2 were collected and
these stocks were stored at –80jC. The FIV-PPR virus
stock had a titer of 0.5  105.1 in these experiments,
determined as described by Hokanson et al. (2000).
Cell culture
Feline PBMC were isolated from EDTA (K3)-treated
whole blood by Histopaque-1077 (Sigma, St. Louis, MO)
density gradient centrifugation (Choi et al., 2000). PBMC
were cultured as described previously with RPMI 1640
(Gibco BRL, Grand Island, NY) supplemented with 10%
heat-inactivated fetal bovine serum (FBS) (Atlas Biologi-
cals, Fort Collins, CO), 50 Ag/ml of gentamicin (Gibco
BRL), 5  105 M 2-mercaptoethanol (Gibco BRL), 2 mM
L-glutamine (Gibco BRL), and 100 units of human recom-
binant IL-2 (hr Il-2) (Gibco BRL) per milliliter (Choi et al.,
2000). Cells were grown at 37jC in a humidified atmo-
sphere of 5% CO2.
Continuous culture of FSF
To develop FSF cell lines, tissues were prepared from skin
plug biopsies of infected cats AUO2, AUO3, AWF1, AZV2,
OLQ5 and uninfected cat OAE5. After five to six passages in
culture, the cells were transformed by transfection of SV40 T
antigen-expressing plasmid DNA (Gift from David Busbee,
Department of Veterinary Anatomy, Texas A&M Universi-ty). The transformed FSF were selected by adding geneticin
(0.5 mg/ml of the medium) (Gibco BRL). The FSF were
cultured in MEM-alpha supplemented by 10% heat-inacti-
vated FBS (Atlas Biologicals), 2 mM L-glutamine (Gibco
BRL), 20 units/ml of epidermal growth factor (Gibco BRL)
and 50 Ag/ml of gentamicin (Gibco BRL).
Preparation of FIV-PPR-infected inducer T cells
Feline T cells were infected with FIV-PPR strain and
irradiated (11,000 rads from a 60Co source provided by the
Nuclear Science Center, Texas Engineering Experiment
Station, College Station, TX) before using as inducer cells
for the stimulation of effector cells, as previously described
(Choi et al., 2000; Song et al., 1992). Briefly, freshly
prepared PBMC were stimulated for 3 days with 5 Ag/ml
of Con A (Sigma). The stimulated cells were infected with
FIV-PPR for 1 h at 37jC. The cells were washed and
cultured in complete RPMI containing 100 units hr Il-2
per milliliter. After 6 days of incubation, virus replication
was monitored using the FIV capsid antigen ELISA. These
FIV-infected cells were cryo-preserved to be used later as
inducer cells.
Preparation of FSF as inducer cells
The gene encoding FIV capsid antigen was amplified by
PCR from FIV-PPR-infected T cells using the following
primers synthesized with BamHI sites at the 5Vends; forward
primer: 5V-CGG GAT CCA CAA ACA GTA AAT GGA GC-
3Vand backward primer: 5V-CGG GAT CCT ATC TCT TGA
CAA GC-3V. The PCR conditions used were 30 s at 94jC, 30
s at 55jC and 45 s at 72jC for 30 cycles. The PCR product
was directly cloned into the TOPO TA cloning vector
(Invitrogen, Carlsbad, CA). The cloned DNA with the
correct orientation for capsid expression was digested by
the BamHI restriction enzyme. The digested DNA was
cleaned by gel extraction kit (Qiagen, Valencia, CA) and
ligated into BamHI-digested SFV vector (Gibco BRL).
SFV-capsid recombinant virus particles were made by
cotransfection of SFV-capsid recombinant mRNA and
SFV-helper-2 mRNA into BHK-21 cells according to the
SFV gene expression system instruction manual (Gibco
BRL). FSF were infected with SFV-capsid recombinant
particles or transfected with the SFV-capsid, SFV-lacZ and
SFV RNA. The SFV vector RNA was prepared by tran-
scribing in vitro from SpeI-linearized recombinant vectors
and transfecting into FSF using DMRIE-C reagent (Gibco
BRL). After 18 h in complete RPMI, the SFV capsid-
expressing FSF were used as inducer cells.
Phenotype enrichment
Negative selection for enrichment of CD8+ T from
freshly isolated PBMC of FIV-PPR-infected cats was per-
formed using a combination of panning and magnetic beads.
Fig. 3. Detection of the FIV capsid sequence in infected FSF by RT-PCR
analysis. FSF were infected with SFV capsid recombinant particles or left
uninfected. cDNA was made from the RNA from the infected and the
uninfected cells and amplified by PCR. PCR analysis was performed using
primers specific for FIV capsid (forward primer 5V-CGGGATCCACAAA-
CAGTAAATGGAGC-3Vand backward primer 5V-CGGGATCCTATCTCTT-
GACAAGC-3V) using cDNA from infected cells (lane 1) or uninfected cells
(lane 2). The arrow indicates the capsid-specific 639-bp PCR product in
lane 1. DNA marker (Lambda DNA/HindIII, Promega, Madison, WI) is
indicated in lane M.
Fig. 4. Immunofluorescent staining of the FIV capsid protein expressed on
FSF. FIV capsid protein expressed on FSF after transfection of FSF with
SFV vector expressing FIV capsid RNA (A). Untransfected FSF cells are
shown in B. Magnification, 200.
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PBMC by incubating the PBMC in complete RPMI at 37jC
in a humidified atmosphere of 5% CO2 for 4 h. The non-
adherent cells were washed once in phosphate-buffered
saline (PBS). The washed cells were then incubated in 1
ml of PBS with 3% FBS containing 500 Al of anti-feline
CD4 monoclonal antibody (CAT30A, gift from Dr. Wayne
Tompkins, North Carolina State University) and 30 Al of
mouse anti-human CD14 monocyte antibody (Clone TUK4,
Dako, Carpinteria, CA) for 30 min at 4jC on a mixer. The
cells were washed once in PBS, resuspended in 1 ml of PBS
with 3% FBS containing M450 dynabeads that had been
coated with goat anti-mouse IgG (Dynal Biotech, Great
Neck, NY) and incubated for 30 min at 4jC on a mixer.
After the bead-bound cells (CD4+ T cells and CD14+ cells)
were magnetically removed, the remaining cells, mostly
CD8+ T cells, were resuspended in 1 ml of PBS with 3%
FBS, gently agitated to release any trapped nonbound cells,
and then magnetically reisolated. The purity of the CD8+ T
cells was confirmed by flow cytometry (data not shown).
Stimulation of effector cells by SFV capsid-expressing
inducer cells
At an effector to inducer cell ratio of 20:1, autologous
irradiated FSF infected with SFV-capsid recombinant virus
particles were added to effector cells from FIV-infected cats
AUO2, AUO3, AWF1, AZV2 and OLQ5 and FIV-unin-
fected cat OAE5 and medium was changed every 3 or 4
days. Expression of capsid antigen on FSF was detected byRT-PCR that amplified and detected the FIV capsid gene
(Fig. 3). After 7 days of stimulation, cell culture super-
natants were collected, stored at 4jC and the FIV-suppres-
sive activity of the supernatants was tested as described
below.
Alternatively, FSF prepared from cat AZV2 were plated
in six-well plates (3  105 cells/well) and were transfected
with SFV-capsid RNA, SFV lacZ RNA or SFV-1 RNA
(vector only without any insert) using DMRIE-C (Gibco
BRL). Five micrograms of RNA was used for each trans-
fection reaction. Expression of SFV-capsid on the FSF was
confirmed by an immunofluorescence assay (IFA) as de-
scribed elsewhere (Brown et al., 1991) (Fig. 4). Expression
of lacZ was confirmed by adding X-galactosidase (Prom-
ega). These inducer cells transfected with SFV-capsid RNA,
SFV-lacZ RNA or SFV RNA were overlaid 18 h after
transfection with autologous or heterologous effector cells
(either fresh PBMC—data not shown or CD8+ T cells—
Figs. 1a–1c) from FIV-infected and -uninfected cats. Every
2 days for 6 days, the non-adherent cells were harvested and
centrifuged at 1200 rpm for 10 min (Jouan, Winchester,
VA), and the supernatants collected and stored at 4jC before
overlaying the cells onto freshly prepared inducer cells.
Controls were non-transfected FSF cultured in the absence
of effector cells, effector cells cultured without FSF and
A.P. Phadke et al. / Virology 320 (2004) 63–7472non-transfected FSF co-cultured with effector cells. The
supernatants collected from these cells on days 2, 4 and 6
were stored at 4jC.
Transwell separation of cells
To assess the role of cell–cell contact in the induction
of the effector cells, the irradiated inducer T cells were
co-cultured with autologous effector PBMC in six-well
tissue culture plates in which the two cell populations
were separated by a 0.45-Am pore size polycarbonate
membrane (Corning Incorporated, Acton, MA) at a ratio
of 1:5 inducer to effector cells in a total volume of 3 ml
of complete RPMI. Inducer cells were also co-cultured
with the effector PBMC, such that the inducer cells and
the effector cells were in contact with each other. PBMC
cultured without any inducer cells were used as controls.
Newly irradiated inducer cells were added to the effector
cells on the third day. The supernatants were collected on
days 3, 6 or 7 and stored at 4jC.
FIV suppression assay
Cell-free supernatants stored at 4jC were ultracentri-
fuged at 35,000 rpm for 2 h (Beckman L7-55 Ultracen-
trifuge, Palo Alto, CA) to remove the residual viral
particles. The supernatants were passed through 0.22-
Am-pore size filters (Pall Corporation, Ann Arbor, MI)
and stored at 4jC. Target cells were prepared from PBMC
of an FIV-uninfected cat after culturing in vitro for 6 days
with Con A and IL-2 (Choi et al., 2000). They were then
infected with the FIV-PPR strain and cultured with super-
natants in a 96-well plate for 10 days at a medium to
supernatant ratio of 1:1. Supernatant and fresh complete
RPMI + hr Il-2 100 units/ml was added to the cells every
3 days. The amount of FIV in the supernatants was
determined by an FIV capsid antigen detection ELISA.
Suppression was considered to be positive when virus
expression was V65% of virus expression in the untreated
controls. Positive controls were FIV-infected PBMC cul-
tured in complete RPMI in the absence of effector cell
supernatants.
Statistics
The differences in FIV replication between infected
control cells and cells in which suppression of FIV was
seen were analyzed with a two-tailed Student’s t test (Ott,
1993). Statistically significant differences were set at a P
value of <0.05.Acknowledgments
We thank Anna Mata, Lynda Case, Angel Tapia, Carrie
Giordano and Kelly Frame for collection of feline bloodsamples. We also thank Dr. Mary Carpino for her help
with collection of the skin plug biopsies from the cats and
Dr. Roger Smith for his assistance with flow cytometry. In
addition, we acknowledge the Nuclear Science Center at
Texas A&M University for irradiation of inducer cells.
This work was funded by National Institute of Allergy and
Infectious Diseases grant AI 32360-01, by Center for
AIDS Research grant 502342, by Morris Animal Founda-
tion grant 96FE-09 and by Dr. Ann Kier, department head
of the Department of Veterinary Pathobiology, Texas A&M
University.References
Appay, V., Nixon, D.F., Donahoe, S.M., Gillespie, G.M., Dong, T., King,
A., Ogg, G.S., Spiegel, H.M., Conlon, C., Spina, C.A., Havlir, D.V.,
Richman, D.D., Waters, A., Easterbrook, P., McMichael, A.J., Row-
land-Jones, S.L., 2000. HIV-specific CD8 (+) T cells produce antiviral
cytokines but are impaired in cytolytic function. J. Exp. Med. 192 (1),
63–75.
Barker, E., 1999. CD8+ cell-derived anti-human immunodeficiency virus
inhibitory factor. J. Infect. Dis. 179 (Suppl. 3), S485–S488.
Barouch, D.H., Letvin, N.L., 2001. CD8+ cytotoxic T lymphocyte
responses to lentiviruses and herpesviruses. Curr. Opin. Immunol. 13
(4), 479–482.
Blackbourn, D.J., Chuang, L.F., Killam Jr., K.F., Chuang, R.Y., 1994.
Inhibition of simian immunodeficiency virus (SIV) replication by
CD8+ cells of SIV-infected rhesus macaques: implications for immu-
nopathogenesis. J. Med. Primatol. 23 (6), 343–354.
Blackbourn, D.J., Mackewicz, C.E., Barker, E., Hunt, T.K., Herndier, B.,
Haase, A.T., Levy, J.A., 1996. Suppression of HIV replication by lym-
phoid tissue CD8+ cells correlates with the clinical state of HIV-infected
individuals. Proc. Natl. Acad. Sci. U.S.A. 93 (23), 13125–13130.
Brinchmann, J.E., Gaudernack, G., Vartdal, F., 1990. CD8+ T cells inhibit
HIV replication in naturally infected CD4+ T cells. Evidence for a
soluble inhibitor. J. Immunol. 144 (8), 2961–2966.
Brown, W.C., Bissey, L., Logan, K.S., Pedersen, N.C., Elder, J.H., Collis-
son, E.W., 1991. Feline immunodeficiency virus infects both CD4+ and
CD8+ T lymphocytes. J. Virol. 65 (6), 3359–3364.
Bucci, J.G., English, R.V., Jordan, H.L., Childers, T.A., Tompkins, M.B.,
Tompkins, W.A., 1998a. Mucosally transmitted feline immunodeficien-
cy virus induces a CD8+ antiviral response that correlates with reduc-
tion of cell-associated virus. J. Infect. Dis. 177 (1), 18–25.
Bucci, J.G., Gebhard, D.H., Childers, T.A., English, R.V., Tompkins, M.B.,
Tompkins, W.A., 1998b. The CD8+ cell phenotype mediating antiviral
activity in feline immunodeficiency virus-infected cats is characterized
by reduced surface expression of the CD8 beta chain. J. Infect. Dis. 178
(4), 968–977.
Charaf, B., Sanhadji, K., Sekkat, S., Farouqui, B., Touraine, J.L., Bensli-
mane, A., 1993. MHC-I non-restricted cytotoxic activity in Macaca
sylvana experimentally inoculated with HIV2 and SIV/mac. Thymus
22 (1), 1–12.
Choi, I.S., Hokanson, R., Collisson, E.W., 2000. Anti-feline immunodefi-
ciency virus (FIV) soluble factor(s) produced from antigen-stimulated
feline CD8(+) T lymphocytes suppresses FIV replication. J. Virol. 74
(2), 676–683.
Clerici, M., Balotta, C., Galli, M., 1996. Soluble HIV suppressive factors:
more than one Holy Grail? Immunol. Today 17 (7), 297–298.
Copeland, K.F., 2002. The role of CD8+ T cell soluble factors in
human immunodeficiency virus infection. Curr. Med. Chem. 9
(20), 1781–1790.
Copeland, K.F., Leith, J.G., McKay, P.J., Kelleher, L., Smaill, F.M., Rosen-
thal, K.L., 1997. CD8+ T cell-mediated suppression of HIV long ter-
A.P. Phadke et al. / Virology 320 (2004) 63–74 73minal repeat-driven gene expression is not associated with improved
clinical status. AIDS 11 (5), 581–586.
Crawford, P.C., Papadi, G.P., Levy, J.K., Benson, N.A., Mergia, A., John-
son, C.M., 2001. Tissue dynamics of CD8 lymphocytes that suppress
viral replication in cats infected neonatally with feline immunodeficien-
cy virus. J. Infect. Dis. 184 (6), 671–681.
Flynn, J.N., Cannon, C.A., Sloan, D., Neil, J.C., Jarrett, O., 1999. Suppres-
sion of feline immunodeficiency virus replication in vitro by a soluble
factor secreted by CD8+ T lymphocytes. Immunology 96 (2), 220–229.
Flynn, J.N., Dunham, S., Mueller, A., Cannon, C., Jarrett, O., 2002. In-
volvement of cytolytic and non-cytolytic T cells in the control of feline
immunodeficiency virus infection. Vet. Immunol. Immunopathol. 85
(3–4), 159–170.
Furci, L., Lopalco, L., Loverro, P., Sinnone, M., Tambussi, G., Lazzarin,
A., Lusso, P., 2002. Non-cytotoxic inhibition of HIV-1 infection by
unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected indi-
viduals. AIDS 16 (7), 1003–1008.
Gebhard, D.H., Dow, J.L., Childers, T.A., Alvelo, J.I., Tompkins, M.B.,
Tompkins, W.A., 1999. Progressive expansion of an L-selectin-negative
CD8 cell with anti-feline immunodeficiency virus (FIV) suppressor
function in the circulation of FIV-infected cats. J. Infect. Dis. 180 (5),
1503–1513.
Geiben-Lynn, R., Kursar, M., Brown, N.V., Kerr, E.L., Luster, A.D., Walk-
er, B.D., 2001. Noncytolytic inhibition of X4 virus by bulk CD8(+)
cells from human immunodeficiency virus type 1 (HIV-1)-infected per-
sons and HIV-1-specific cytotoxic T lymphocytes is not mediated by
beta-chemokines. J. Virol. 75 (17), 8306–8316.
Gomez, A.M., Smaill, F.M., Rosenthal, K.L., 1994. Inhibition of HIV
replication by CD8+ T cells correlates with CD4 counts and clinical
stage of disease. Clin. Exp. Immunol. 97, 68–75.
Hohdatsu, T., Okubo, M., Koyama, H., 1998. Feline CD8+ T cell non-
cytolytic anti-feline immunodeficiency virus activity mediated by a
soluble factor(s). J. Gen. Virol. 79 (Pt 11), 2729–2735.
Hohdatsu, T., Miyagawa, N., Ohkubo, M., Kida, K., Koyama, H., 2000.
Studies on feline CD8+ T cell non-cytolytic anti-feline immunodeficien-
cy virus (FIV) activity. Arch. Virol. 145 (12), 2525–2538.
Hohdatsu, T., Sasagawa, T., Yamazaki, A., Motokawa, K., Kusuhara, H.,
Kaneshima, T., Koyama, H., 2002. CD8+ T cells from feline immuno-
deficiency virus (FIV) infected cats suppress exogenous FIV replication
of their peripheral blood mononuclear cells in vitro. Arch. Virol. 147
(8), 1517–1529.
Hokanson, R.M., TerWee, J., Choi, I.S., Coates, J., Dean, H., Reddy, D.N.,
Wolf, A.M., Collisson, E.W., 2000. Dose response studies of acute
feline immunodeficiency virus PPR strain infection in cats. Vet. Micro-
biol. 76 (4), 311–327.
Hsueh, F.W., Walker, C.M., Blackbourn, D.J., Levy, J.A., 1994. Suppres-
sion of HIV replication by CD8+ cell clones derived from HIV-infected
and uninfected individuals. Cell. Immunol. 159 (2), 271–279.
Jeng, C.R., English, R.V., Childers, T., Tompkins, M.B., Tompkins, W.A.,
1996. Evidence for CD8+ antiviral activity in cats infected with feline
immunodeficiency virus. J. Virol. 70 (4), 2474–2480.
Kannagi, M., Chalifoux, L.V., Lord, C.I., Letvin, N.L., 1988. Suppression
of simian immunodeficiency virus replication in vitro by CD8+ lym-
phocytes. J. Immunol. 140 (7), 2237–2242.
Kootstra, N.A., Miedema, F., Schuitemaker, H., 1997. Analysis of CD8+ T
lymphocyte-mediated nonlytic suppression of autologous and heterolo-
gous primary human immunodeficiency virus type 1 isolates. AIDS
Res. Hum. Retrovir. 13 (8), 685–693.
Landay, A.L., Mackewicz, C.E., Levy, J.A., 1993. An activated CD8+ T
cell phenotype correlates with anti-HIV activity and asymptomatic clin-
ical status. Clin. Immunol. Immunopathol. 69 (1), 106–116.
Le Borgne, S., Fevrier, M., Callebaut, C., Lee, S.P., Riviere, Y., 2000.
CD8(+)-cell antiviral factor activity is not restricted to human immu-
nodeficiency virus (HIV)-specific T cells and can block HIV replication
after initiation of reverse transcription. J. Virol. 74 (10), 4456–4464.
Levy, J.A., 2001. The importance of the innate immune system in control-
ling HIV infection and disease. Trends Immunol. 22 (6), 312–316.Levy, J.A., Mackewicz, C.E., Barker, E., 1996. Controlling HIV pathogen-
esis: the role of the noncytotoxic anti-HIV response of CD8+ T cells.
Immunol. Today 17 (5), 217–224.
Levy, J.A., Hsueh, F., Blackbourn, D.J.,Wara, D.,Weintrub, P.S., 1998. CD8
cell noncytotoxic antiviral activity in human immunodeficiency virus-
infected and -uninfected children. J. Infect. Dis. 177 (2), 470–472.
Mackewicz, C.E., Ortega, H.W., Levy, J.A., 1991. CD8+ cell anti-HIV
activity correlates with the clinical state of the infected individual.
J. Clin. Invest. 87 (4), 1462–1466.
Mackewicz, C.E., Yang, L.C., Lifson, J.D., Levy, J.A., 1994. Non-cytolytic
CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet 344
(8938), 1671–1673.
Mackewicz, C.E., Garovoy, M.R., Levy, J.A., 1998. HLA compatibility
requirements for CD8(+)-T-cell-mediated suppression of human immu-
nodeficiency virus replication. J. Virol. 72 (12), 10165–10170.
Moriuchi, H., Moriuchi, M., Combadiere, C., Murphy, P.M., Fauci, A.S.,
1996. CD8+ T-cell-derived soluble factor(s), but not beta-chemokines
RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication
in monocyte/macrophages. Proc. Natl. Acad. Sci. U.S.A. 93 (26),
15341–15345.
Mosoian, A., Teixeira, A., Caron, E., Piwoz, J., Klotman, M.E., 2000.
CD8+ cell lines isolated from HIV-1-infected children have potent sol-
uble HIV-1 inhibitory activities that differs from beta-chemokines. Viral
Immunol. 13 (4), 481–495.
Ott, R.L., 1993. An Introduction to Statistical Methods and Data Analysis.
Duxbury Press, Belmont, CA, pp. 197–258.
Pedersen, N.C., Ho, E.W., Brown, M.L., Yamamoto, J.K., 1987. Isolation
of a T-lymphotropic virus from domestic cats with an immunodeficien-
cy-like syndrome. Science 235 (4790), 790–793.
Pedersen, N.C., Yamamoto, J.K., Ishida, T., Hansen, H., 1989. Feline im-
munodeficiency virus infection. Vet. Immunol. Immunopathol. 21 (1),
111–129.
Pollack, H., Zhan, M.X., Safrit, J.T., Chen, S.H., Rochford, G., Tao,
P.Z., Koup, R., Krasinski, K., Borkowsky, W., 1997. CD8+ T-cell-
mediated suppression of HIV replication in the first year of life:
association with lower viral load and favorable early survival. AIDS
11 (1), F9–F13.
Powell, J.D., Yehuda-Cohen, T., Villinger, F., McClure, H.M., Sell, K.W.,
Ahmed-Ansari, A., 1990. Inhibition of SIV/SMM replication in vitro by
CD8+ cells from SIV/SMM infected seropositive clinically asymptom-
atic sooty mangabeys. J. Med. Primatol. 19 (3–4), 239–249.
Rosok, B., Voltersvik, P., Larsson, B.M., Albert, J., Brinchmann, J.E., Asjo,
B., 1997. CD8+ T cells from HIV type 1-seronegative individuals sup-
press virus replication in acutely infected cells. AIDS Res. Hum. Retro-
vir. 13 (1), 79–85.
Song, W., Collisson, E.W., Billingsley, P.M., Brown, W.C., 1992. Induction
of feline immunodeficiency virus-specific cytolytic T-cell responses
from experimentally infected cats. J. Virol. 66 (9), 5409–5417.
Stranford, S.A., Skurnick, J., Louria, D., Osmond, D., Chang, S.Y., Snin-
sky, J., Ferrari, G., Weinhold, K., Lindquist, C., Levy, J.A., 1999. Lack
of infection in HIV-exposed individuals is associated with a strong
CD8(+) cell noncytotoxic anti-HIV response. Proc. Natl. Acad. Sci.
U.S.A. 96 (3), 1030–1035.
Toso, J.F., Chen, C.H., Mohr, J.R., Piglia, L., Oei, C., Ferrari, G., Green-
berg, M.L., Weinhold, K.J., 1995. Oligoclonal CD8 lymphocytes from
persons with asymptomatic human immunodeficiency virus (HIV) type
1 infection inhibit HIV-1 replication. J. Infect. Dis. 172 (4), 964–973.
Walker, C.M., 1993. Non-cytolytic control of HIV replication by CD8+ T
cells. Semin. Immunol. 5 (3), 195–201.
Walker, C.M., Moody, D.J., Stites, D.P., Levy, J.A., 1986. CD8+ lympho-
cytes can control HIV infection in vitro by suppressing virus replication.
Science 234 (4783), 1563–1566.
Walker, C.M., Erickson, A.L., Hsueh, F.C., Levy, J.A., 1991a. Inhibition of
human immunodeficiency virus replication in acutely infected CD4+
cells by CD8+ cells involves a noncytotoxic mechanism. J. Virol. 65
(11), 5921–5927.
Walker, C.M., Thomson-Honnebier, G.A., Hsueh, F.C., Erickson, A.L.,
A.P. Phadke et al. / Virology 320 (2004) 63–7474Pan, L.Z., Levy, J.A., 1991b. CD8+ T cells from HIV-1-infected indi-
viduals inhibit acute infection by human and primate immunodeficiency
viruses. Cell. Immunol. 137 (2), 420–428.
Yamamoto, J.K., Sparger, E., Ho, E.W., Andersen, P.R., O’Connor, T.P.,
Mandell, C.P., Lowenstine, L., Munn, R., Pedersen, N.C., 1988. Path-
ogenesis of experimentally induced feline immunodeficiency virus in-
fection in cats. Am. J. Vet. Res. 49 (8), 1246–1258.
Yang, O.O., Kalams, S.A., Trocha, A., Cao, H., Luster, A., Johnson, R.P.,Walker, B.D., 1997. Suppression of human immunodeficiency virus
type 1 replication by CD8+ cells: evidence for HLA class I-restricted
triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71 (4),
3120–3128.
Zanussi, S., Simonelli, C., D’Andrea, M., Caffau, C., Clerici, M., Tirelli,
U., DePaoli, P., 1996. CD8+ lymphocyte phenotype and cytokine
production in long-term non-progressor and in progressor patients with
HIV-1 infection. Clin. Exp. Immunol. 105 (2), 220–224.
